Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-23-033230
Filing Date
2023-09-20
Accepted
2023-09-20 17:15:35
Documents
12
Period of Report
2023-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 44410
  Complete submission text file 0001493152-23-033230.txt   221405

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE zvsa-20230913.xsd EX-101.SCH 3012
3 XBRL LABEL FILE zvsa-20230913_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE zvsa-20230913_pre.xml EX-101.PRE 22357
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3533
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41184 | Film No.: 231267166
SIC: 2834 Pharmaceutical Preparations